Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$183.34 USD

183.34
910,038

-2.34 (-1.26%)

Updated Oct 7, 2024 04:00 PM ET

After-Market: $183.34 0.00 (0.00%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon

The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon

Mark Vickery headshot

Top Stock Reports for Union Pacific, NextEra & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), NextEra (NEE) and Biogen (BIIB).

AstraZeneca Gives Detailed Data From Calquence Leukemia Study

AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

Biogen (BIIB) Gains But Lags Market: What You Should Know

Biogen (BIIB) closed the most recent trading day at $230.86, moving +0.19% from the previous trading session.

Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know

Biogen (BIIB) closed the most recent trading day at $227.33, moving +1.33% from the previous trading session.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Biogen Reports Interim Phase III Data on Diroximel Fumarate

Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.

Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs

Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.

PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts

PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen (BIIB) closed at $223.40, marking a -0.95% move from the previous day.

Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma

Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.

Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems

Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.

Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound?

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Benjamin Rains headshot

Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)

Let's look at what investors should expect from some of the more notable tech companies still left to report: Veeva Systems Inc. (VEEV), Workday, Inc. (WDAY), and Palo Alto Networks, Inc. (PANW).

The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific

The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.

Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Mark Vickery headshot

Top Research Reports for Chubb, Las Vegas Sands & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Chubb (CB), Las Vegas Sands (LVS) and Biogen (BIIB).

Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.

Kinjel Shah headshot

5 Low Price-to-Book Value Stocks for Great Returns

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on String of Q1 Earnings Beats

Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex

The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex